QUICK ANSWER · AEO / GEO
A long-acting amylin analogue under clinical development; combination and monotherapy evidence should not be conflated.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- Long-term monotherapy outcomes and risks from Phase 3 RENEW, for which results have not yet been posted in the registry
- Rare adverse events in larger and more diverse populations
- The indications, labelling, contraindications and regulatory conditions if approval is granted in the future
- The quality and actual composition of products sold outside trials
What limits these conclusions?
- Major studies were funded by the developer and included authors affiliated with the company. Study durations and populations were limited. CagriSema results cannot fully isolate the effects of cagrilintide, and cross-study outcome comparisons with semaglutide, tirzepatide or other molecules are not head-to-head evidence.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://annualreport.novonordisk.com/2025/strategic-aspirations/innovation-and-therapeutic-focus.html
- https://clinicaltrials.gov/study/NCT07220642
- https://clinicaltrials.gov/study/NCT07220759
- https://pubmed.ncbi.nlm.nih.gov/34798060/
- https://pubmed.ncbi.nlm.nih.gov/37364590/
- https://pubmed.ncbi.nlm.nih.gov/40544433/
- https://cms.mhra.gov.uk/pip/mhra-102266-pip01-25
- https://www.ema.europa.eu/en/documents/pip-decision/p-241-2022-ema-decision-8-july-2022-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-cagrilintide-semaglutide-emea-003059-pip01-21_en.pdf
FAQ · ANSWER ENGINE
Frequently asked questions
What is Cagrilintide?
Cagrilintide is described pharmacologically as Long-acting amylin analogue. A long-acting amylin analogue under clinical development; combination and monotherapy evidence should not be conflated.
Does Cagrilintide have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Cagrilintide approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.